Telomir-1 restores lifespan to near-normal in preclinical progeria model

Telomir Pharmaceuticals, Inc.

In C. elegans with wrn-1 mutation (Werner Syndrome model), Telomir-1 restored lifespan to near-normal levels.
Progeria causes rapid aging in children; these results suggest potential for Telomir-1 to address cellular aging issues.
Telomir Pharmaceuticals (Nasdaq: TELO) announced the findings in an SEC filing on Jan 7, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.